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Abstract
Background: Best practice for statistical methodology in cell-based dose-response
studies has yet to be established. We examine the ability of MANOVA to detect
trait-associated genetic loci in the presence of gene-gene interactions. We present a
novel Bayesian nonparametric method designed to detect such interactions.
Results: MANOVA and the Bayesian nonparametric approach show good ability to
detect trait-associated genetic variants under various possible genetic models. It is
shown through several sets of analyses that this may be due to marginal effects being
present, even if the underlying genetic model does not explicitly contain them.
Conclusions: Understanding how genetic interactions affect drug response continues
to be a critical goal. MANOVA and the novel Bayesian framework present a trade-off
between computational complexity and model flexibility.
Keywords: Dose-response, Epistasis, Bayesian nonparametric, Neural network,
Machine learning
Background
Understanding the genetic factors underlying differential drug response continues to be
a primary goal in pharmecogenomics and drug development. Association studies based
on the use of in vitro cell lines, such as lymphoblastoid cell lines (LCLs), are becoming
an attractive alternative to traditional, human based clinical trials [1-3]. Cell lines offer
increased sample sizes relative to traditional studies, resulting in higher statistical power
to detect genetic variants that potentially drive drug response. However, the challenges
offered by these unique data has yet to be comprehensively studied and evaluated.
Recent work has shown that considering the full set dose-responses instead of sum-
mary statistics can greatly increase the power to detect trait-associated genetic variants
[3-7]. This new approach is based on a statistical method known asmultivariate analysis
of variance or MANOVA, which is an extension to the well known analysis of variance
(ANOVA) framework. Recent studies using a MANOVA-based framework have revealed
genetic loci associated with differential responses in anti-cancer agents [3,4]. However,
little study to date has been done to investigate the potential effect of gene-gene inter-
actions, or epistasis, which is thought to be a critical piece in the genetic architecture of
many complex phenotypes [8-10].
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The role of epistasis in complex genetic disease continues to be debated in the litera-
ture, as well as the potential of epistasis to solve the so-call missing heritability problem
[11-13]. Recent work has validated the role of epistasis in complex disease in humans
[14] and drosophila [15]. To date, nearly all of the work on epistasis has focused on case-
control studies, or single-valued QTLs (e.g. gene expression). No work has yet been done
to understand how epistasis may affect the unique, multiresponse data that comes from
dose-response studies.
To investigate how genetic interactions may affect the power of MANOVA we per-
formed a simulation study across several plausible models of SNP-driven dose-response
involving multiple loci. In addition to investigating the MANOVA approach, we develop
a novel Bayesian nonparametric model that is capable of automatically accounting for
genetic interactions in multi-response data. We have previously developed a Bayesian
neural network testing framework [16] for case-control studies that is capable of iden-
tifying trait-associated loci in the presence of genetic interactions in a computationally
tractable way. In this study, we extend this framework to model dose-response data that
contain multiple continuous responses. Through comparisons of several possible genetic
models, we hope to gain insight as to how deviation from an additive model (i.e. the
presence of epistasis) may affect the statistical power of each method.
Methods
Multivariate analysis of variance (MANOVA)
First we provide a brief review of the MANOVA framework for dose-response studies. In
a dose-response study, a chemical is administered to a cell culture across several concen-
trations and a quantitative response (e.g mRNA expression or total ATP) is measured at
each concentration. Until recently, the prevailing methodology in dose-response associa-
tion mapping has been to fit a parametric logistic function, known as the hill-slopemodel,
as a function of concentration ci:






where Max,Min are the upper and lower asymptotes, and w is the hill-slope. The IC50
parameter is the concentration at which the response is 50% of maximum and is usu-
ally given special importance because it a measure of chemical potency. The IC50 is
then treated as quantitative trait and quantitative trait locus (QTL) mapping techniques
attempt to identify loci that appear to be associated with this trait. In general, this
approach results in a drastic loss of power relative to potential alternatives [7,17]. Recent
work has shown that multivariate analysis of variance (MANOVA) has high power across
a wide variety of possible dose-response relationships, making it an attractive option for
genome-wide association mapping.
Let xi =< xi1, . . . , xip >T be a vector containing the genotypes of all p markers for
individual i, where each xij ∈ {0, 1, 2} contains the number of instances of the minor allele.
Let yi =< yi1, . . . , yik > be the vector containing the responses for subject i at each of
the k doses, where each yik ∈ R. MANOVA models the conditional expected value of y ,
given xi, E[ yik|xi] as a linear function:
E[ yik|xi]= β0 + βTk xi (2)
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The least-squares estimator for Bp×k =< β1, . . . ,βp > is given by (XTX)−1XTY . where
Xn×p =< xi, . . . , xn >T and Yn×k =< y1, . . . , yn >. For the case when n < p or when X is
not full rank, as is often the case for GWASs, smaller sub-models may be fit and analyzed.
For example, if 1 million markers are genotyped for only 1,000 individuals, each marker
may be fit separately along with any possible confounding covariates such as age, gender,
or sub-population status.
This model has several advantages including interpretability and a well understood
theoretical foundation that allows for null-hypothesis significance testing. However, the
linearity assumption may be somewhat restrictive and if a trait is influenced or deter-
mined by interactions between markers, this model may only partially capture the true
relationship. One approach to lessen this restriction would be to explicitly include all
interactions as terms in the model, and build the linear model on this expanded set of
covariates. However, this quickly becomes infeasible for even 2nd order interactions. In a
study containing one million markers, there are approximately 5 ∗ 109 possible 2nd order
interactions. The computational issues associated with this approach make it infeasible,
as do the corresponding multiple testing issues associated with testing billions or trillions
of simultaneous hypotheses.
A different approach to account for interactions would be to use a class of models that
relax the linearity assumption and impose very little structural constraints on the relation-
ship between xi and yik . Neural networks are one such approach and have a rich history
of success in the machine learning and genetic epidemiology [18,19]. Neural nets come
with several theoretical guarantees that make them appealing for modeling potentially
nonlinear functions. Perhaps the most germane property is given by the universal func-
tion approximation theorem [20], which states that a sufficiently complex neural network
is capable of modeling any smooth function on a compact set to an arbitrary degree of
precision. This theorem ensures that a neural network is capable in principle of modeling
a rich class of functions between input and output. Subsumed in the class of functions
neural networks can represent is the linear model used by MANOVA. Thus, if the true
model is indeed linear, the relationship learned by the neural network would automati-
cally collapse to represent the linear mapping between input and output, while if the true
relationship is more complex, it will include any nonlinearities without having to spec-
ify them a priori. In the next section we present and develop a Bayesian neural network
framework for dose-response studies.
Bayesian neural networks
Bayesian neural networks represent an extension to the familiar neural network frame-
work. Recent work in [16] has shown they can successfully model genetic interactions
in case-control studies. Here we present an augmented design capable of modeling
multi-response data, such as the kind observed in dose-response studies.
Neural networks construct a hierarchical representation where inputs are transformed
into (potentially) nonlinear features that can undergo further nonlinear transformations.
For our purposes we consider networks with only one such transformation. Networks
with this architecture are often described as having one hidden layer, because the graph-
ical model describing the network has one such transformation occurring at the same
hierarchical level between input and output. Figure 1 shows a graphical depiction of a
neural network model for dose-response data.
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Figure 1 Graphical depiction of a neural network with several output units. The blue nodes on the
bottom represent SNPs in MAF coding, the orange nodes represent the hidden unit functions in Equation (3),
and the red nodes at the top represent the estimated response for each of the concentrations measured.
This architecture allows the network to model the response at each concentration as a nonlinear
combination of the input SNPs.
The first layer of Figure 1 shows the input SNPs represented as the number of minor
alleles present at each of the pmarkers. The inputs are fed into several hidden units, where
each hidden unit, hj(xi), performs the following nonlinear logistic transformation:
hj(xi) = 11 + exp (− (aj + xTi wj)) (3)
where wj is a p × 1 vector of weights associated with hidden unit j, and aj is the unit’s





output unit takes a linear combination of the outputs from the hidden units, using the
following form:
fk(xi) = αk +
H∑
j=1
hj(xi) ∗ βkj (4)
where αk is the bias and βkj is the weight given to the output from hidden unit j, for
output unit k. Equations (3) and (4) form the base neural network model. To incorporate
this into a Bayesian framework, we must define several additional components. Bayesian
methods define a posterior distribution over possible parameter values. The posterior
distribution combines a prior distribution, that is updated based on the observed data.
Letting θ represent all of the network parameters in Equations (3), (4), Bayes’ rule defines
the posterior distribution of θ , given the data xi, yi:
p (θ |xi, yi) = L (θ |xi, yi) p(θ)∫ L (θ |xi, yi) p(θ)dθ (5)
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where p(θ) is the prior distribution for the network parameters and L (θ |xi, yi) is the likeli-
hood function. The network’s output for each observation,fik(xi), is given an independent
Gaussian likelihood with mean fik(xi) and unit variance, shown below:
L (θ |xi, yi) = exp
(





There are many choices for the prior, p(θ), but the one adopted here is the Automatic
Relevance Determination (ARD) prior [21,22]. Briefly, the ARD prior groups weights in
the hidden layer together in a meaningful way. Weights that are connected to the same
SNP across hidden units are given a shared parameter that controls how large the values
they take on are allowed to become. Specifically, the weights in each hidden unit that are






σ 2j ∼ IG (α0,β0) (8)
where N(·, ·) and IG(·, ·) represent Normal and Inverse-Gamma densities, respectively.
This prior allows the network to automatically determine which inputs are the most rel-
evant. If SNP j seems to be related to the response, then σ 2j will be concentrated around
large values in the posterior. We have previously developed a Bayesian framework that
allows for testing of variable importance relative to a null model [16]. This framework pro-
vides a posterior probability of each SNP’s involvement in the response and is capable of
being applied to continuous, dose-response data in addition to the case-control scenario
for which it was originally developed.
The denominator of (5) is an integral that, in high-dimensions, is intractable. Thus
stochastic integration techniques, such as Markov Chain Monte Carlo (MCMC) are
often used. MCMC algorithms are able to draw samples from the posterior distribu-
tion p(θ |xi, yi) and only require the ability to evaluate L(θ |xi, yi)p(θ) for specific values
of θ . However, popular algorithms such as the well known random-walk Metropolis-
Hastings (RW-MH) [23,24] explore the posterior distribution too slowly to be useful in
a high-dimensional setting. Recently an algorithm known as Hamiltonian Monte Carlo
(HMC) has been shown to explore high-dimensional posterior distributions much more
efficiently by leveraging information about the posterior’s gradient, which guides the sim-
ulation to regions of high probability. This efficiency does not come free, as evaluation of
the gradient must be done 10s to 1000s of times per iteration, possibility limiting HMC’s
usefulness when the number of parameters is large. To enable the use of HMC on com-
plex models in high-dimensions, we have developed a GPU-based sampling scheme that
allows neural network models to be used on large datasets [25]. A graphical overview of
the entire Bayesian neural network procedure is provided in Figure 2.
This framework comes with several advantages relative to the MANOVA approach. As
discussed previously, the relaxation of the linear assumption allows for a broader class of
possible genetic architectures to be detected. Additionally, the BNN approach provides a
nonparameteric procedure for variable selection while MANOVA relies on normality of
errors for its testing procedure to be valid. For instance, p-values from a MANOVA anal-
ysis may not be valid for scenarios in which the number of individuals for one genotype
is rare (e.g. very few homozygotes for the minor allele). Additionally, normalization pro-
cedures must often be performed in order to ensure the error distributions conform as
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Figure 2 Overview of the Bayesian neural network method for dose-response studies. First the
network architecture is established and transferred along with the data to GPU memory. The HMC simulation
is performed on the GPU and the samples are then transferred back to main memory. The posterior for each
SNP’s ARD parameter is compared to the null distribution. Bayesian posterior probabilities are computed to
assess how likely each SNP is to be involved in determing drug-response. In the right panel SNP 1 shows little
evidence of being involved with this trait while SNP P has strong evidence of playing a role.
closely as possible to the assumed distribution. In contrast, due the lack of strict assump-
tions required by the Bayesian neural network framework, there is no reason in principle
why a BNN would be affected by any of these issues.
Results and discussion
We investigated three plausible relationships between genotype and drug-response. For
all simulations a Bayesian neural network with 10 hidden units was used. The HMC sim-
ulation was performed for 375 iterations, with the first 25 discarded as burn-in. For the
HMC sampler a step-size value of 0.02, a momentum-persistence value of 0.75, and a tem-
perature value of 1000 were used. The ARD hyper-parameter values were set to α0 = 3
and β0 = 1while the output layer used α0 = 0.1 and β0 = 0.1, andwe used anARD cut-off
value of 0.4. The ARD hyper-parameters, α0, β0 control the shape and scale (respectively)
of the inverse-gamma prior distribution in the ARD hierarchy. This prior distribution
controls the degree to which weights in the hidden layer are constrained, relative to a
standard neural network. In our experience, the network is relatively insensitive to these
values but please see [16] for the explicit role these parameters play. Each response was
normalized to have mean 0, unit variance. All BNN code was written in Python and is
avilable at https://github.com/beamandrew/BNN.
We used a Bonferonni cut-off value of p < 0.05 for the MANOVA procedure.
MANOVA was conducted using the manova() function in R. Processing each file file
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took the BNN approximately 1 minute, while the MANOVA procedure took approxi-
mately 5 seconds for all simulation settings.
Additive model
As a baseline for the Bayesian neural network model, we first performed a simulation
study using a simple additive model involving 2 loci. We generated a mean dose-response
for each concentration, μ =< μ1, . . . ,μ6 >, according to the hill-slope model in
Equation (1):
μk = 1 − 11 + x−1.5k
(9)
for k ∈ {1, . . . 6} and x = 10−4 ∗ {0.03125, 0.0625, 0.10, 0.25, 0.5, 1.25}, resulting in a mean
dose-response curve for 6 concentrations. Deviations from the mean induced by SNP sta-
tus were generated according to a linear model plus a heteroskedastic noise term, yielding
an observation i at each concentration, yik :
yik = μk ∗
(
1 + θ2 ∗ S1 −
θ
2 ∗ S2 + 
)
(10)
where  ∼ N(0, 0.1) and S1, S2 ∈ {0, 1, 2} represent number of minor alleles at the two
causal loci, and θ ∈[ 0, 1] represents the effect size of each SNP. In this model being
homozygous for the minor allele causes a θ% change relative to the baseline mean,μk . For
example, θ = 0.02 would correspond to a 2% change for a subject that is homozygous for
the minor allele at S1 while being homozygous for the major allele at S2:
yk = μk ∗
(
1 + 0.022 ∗ 2 −
0.02
2 ∗ 0 + 
)
= μk + μk ∗ 0.02 + k
Also note that one locus (S1) is associated with increased drug response while the
other locus (S2) confers a decreased average response. To evaluate the sensitivity of both
MANOVA and BNN to effect size (θ ) and minor allele frequency (MAF), we simulated
data sets for θ = {0.01.0.02, 0.03, 0.04, 0.05} and MAF = {0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5}.
For each combination of θ andMAF, we generated 100 data sets resulting in 3500 data sets
used in evaluation. Each dataset contained 2,000 observations and 998 background SNPs.
Background SNPs were generated according to a random MAF, ranging uniformly from
0.01 to 0.5. For each parameter combination, the number of times out of 100 eachmethod
correctly identified both causal SNPs as an estimate of statistical power. The results are
shown in Figure 3.
Both BNNs and MANOVA display good power across a variety of parameter combi-
nations, with MANOVA having a slight edge for a few parameter combinations. This is
expected as MANOVA is testing the linear hypothesis directly, while the BNN is testing a
much more general hypothesis.
Additive model with interactions
Next, we considered an additive model with an interaction term, shown below.
yk = μk ∗
(
1 + θ2 ∗ S1 −
θ
2 ∗ S2 +
θ
2 ∗ S1 ∗ S2 + 
)
(11)
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Figure 3 Power results for the additive model. The power for the Bayesian neural network (BNN) model is
shown in blue while MANOVA is shown in orange. Solid lines indicate the power to detect both loci, while
the dashed lines indicate power to detect at least one of the causal loci.
In this model there is deviation from additivity induced by the the interaction term
S1 ∗ S2. We again swept over the same range of values for θ and MAF as done previously.
The results are shown in Figure 4.
Again, both methods appear to have good power across a wide spectrum of parameter
values. However, MANOVA does not perform as well as for larger values of MAF. The
BNN also experiences a loss of power for the highest level of MAF. For most parameter
combinations, the BNN outperformed MANOVA.
Purely interactive model
Finally, we investigated a model in which the SNPs affect the response only through an
interaction, shown below. The results are shown in Figure 5.
yk = μk ∗
(
1 + θ2 ∗ S1 ∗ S2 + 
)
(12)
Perhaps surprisingly, MANOVA displays good power to detect the causal loci for sev-
eral parameter combinations, despite the true model ostensibly lacking any marginal
effects. Both methods struggled for smaller values of MAF, but this is expected due the
relatively rare nature of positive responses for small levels of MAF.
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Figure 4 Power results for the additive model with interactions. The power for the Bayesian neural
network (BNN) model is shown in blue while MANOVA is shown in orange. Solid lines indicate the power to
detect both loci, while the dashed lines indicate power to detect at least one of the causal loci.
Further analysis of simulated models
The results of the preceding section motivated a more in-depth analysis of the reasons
behind MANOVA’s apparent ability to detect models that only contain interactions and
the reduced ability by both methods to detect the model containing main effects and an
interaction term. The apparent loss of power by bothmethods for higher values ofMAF in
Figure 4may be an artifact of the specific simulation parameters used. Notice for example,
that both MANOVA and BNNs have good power to detect one locus for all simulated
scenarios, as evidenced by the dotted line. This suggests that the loss of power under this
model is due to the decreased ability to detect the second locus (S2), as examination of the
raw simulation results indicates this locus was rarely identified as significant. To examine
this hypothesis, we will assume a more general population genetics framework and then
reexamine the results of the simulatedmodels in the previous section as specific instances
of this broader viewpoint.
Amarginal effect is the expected value of yik given the status at one locus, averaged over
all possible values for all other loci. Since the MANOVA procedure only detects marginal
effects, a deeper understanding of how they may manifest in these putative models of
genetic influence may be valuable. What we intend to show is that the discrete nature of
the minor allele coding can introduce artifacts such as main effects in models where none
are explicitly present and how marginal effects are attenuated by an interaction term in
models containing both. First, we will examine the marginal effect of having a specified
genotype at one locus (e.g. S2 = 1) independently of the status at the other locus, and
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Figure 5 Power results for the purely interactive mode. The power for the Bayesian neural network (BNN)
model is shown in blue while MANOVA is shown in orange. Solid lines indicate the power to detect both loci,
while the dashed lines indicate power to detect at least one of the causal loci.
determine generally how this marginal effect changes under different simulated models
as a function of effect size and MAF.
For the moment assume we an infinite population of individuals and we are interested
in the relationship between two loci S1 and S2 and a quantitative trait, y. Let pxy be the
proportion of individuals containing x copies of the minor allele for locus S1 and y copies
of the minor allele for locus S2. As done previously in Equation (11), assume that the
expected value of y, E[ y] is given by an additive relationship:
E[ y]= β1 ∗ S1 + β2 ∗ S2 (13)
where β1,β2 are the effects of having the S1, S2 genotypes, respectively. Consider the
marginal effect of having the genotype S2 = 1. The conditional expectation of y given
S2 = 1, E(y|S2 = 1), can be computed using the law of total probability, with a weighted







E (y|S2 = 1, S1 = i) ∗ pi1 (14)




] = E [y|S2 = 1, S1 = 0] · p01 + E [y|S2 = 1, S1 = 1] · p11
+ E [y|S2 = 1, S2 = 2] · p21
= β2 · p01 + (β1 + β2) · p11 + (2β1 + β2) · p21
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] = β1 · (p11 + 2p21) + β2 · (p01 + p11 + p21) (15)
Let the conditional expectation shown in Equation 15 be referred to as the marginal
effect of S2 = 1 under the additive model, or μA. Now consider that instead of following
a simple additive model, the expected value of y is given by an additive model plus an
interaction term, shown below:
E[ y]= β1 ∗ S1 + β2 ∗ S2 + β3 ∗ (S1 · S2) (16)
Again, using a similar approach as before and summing over all possibilities for S1 the




] = β1 (p11 + p21) + β2 (p01 + p11 + p21) + β3 (p11 + 2p21) (17)
Let this expected value be referred to asμAI . Equations (15),(17) give themarginal effect
of having the genotype S1 = 1 under an additive model and an additive model with an
interaction for arbitrary effect sizes and for arbitrary genotype frequencies. Note that if
β1,β2,β3 > 0, then μAI > μA or the marginal effect under the model with interactions
would be larger, thus MANOVA would have higher power to detect this SNP as causal.
However, using the values used in the simulation (β1 = β3 = θ2 ,β2 = − θ2 ) the equations
reduce to the following expressions:
μA = −θ2 (p01 − p21)
μAI = −θ2 (p01 − p11 − 2p21)
Here it is clear that |μAI | < |μA| since pxy > 0 ∀x, y. This is due to the negative S2
effect, which induces a smaller marginal effect for this locus under the additive model
with an interaction. This explains why in the simulations the power to detect this locus
was reduced when compared to the purely additive model. The reason MANOVA has
reduced power when MAF is high because the interaction term appears more often and
since it has the opposite sign as the S2 locus, it effectively cancels out the response, making
it appear as if S2 has a smaller marginal effect. Table 1 shows the values for μAI and μA
for each possible level of S2 for the effect sizes used in the simulations (i.e. β1 = β3 =
θ
2 ,β2 = − θ2 ):
Note that all of the marginal effects for S2 are smaller than or equal to the additive
models marginal effect size. This explains why there was a decrease in power to detect S2
by MANOVA in the simulations.
Now we turn to the model without any explicit marginal effects and examine if there
are indeed any marginal effects present. Recall the purely interactive model is E[ y]= S1 ∗
S2 ∗ β3. Using the same analysis procedure as before we can calculate the marginal effect
under an interactive model, μI for each level of S2. This is shown in Table 2:
Table 1 Relationship beteweenμAI andμA for each possible level of S2
S2 Status μAI μA |μAI| ? |μA|
0 θ2 (p10 + 2p20) θ2 (p10 + 2p20) =
1 − θ2 (p01 − p11 − 2p21) − θ2 (p01 − p21) <
2 − θ2 (2p02 − p12 + 2p22) − θ2 (2p02 + p12) <
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Table 2 Relationship beteweenμI andμA for each possible level of S2
S2 Status μI μA |μI| ? |μA|
0 0 θ2 (p10 + 2p20) <
1 θ2 (p11 + 2p21) − θ2 (p01 − p21) ?
2 θ2 (p12 + 4p22) − θ2 (2p02 + p12) ?
A ? in the third column indicates that no strict inequality can be determined.
Here there is no clear, strict inequality, but assessments can be made for specific values
of p01, p11, p21. Note that in general |μI | > 0 in all instances so there will always be some
amount of marginal effect present for this model. For many values of MAF, |μI | will be
a non-trivial amount relative to |μA| resulting in high power for a model can only detect
additive effects, such as MANOVA. Thus the reason MANOVA in Figure 5 has good
power for high values of MAF is because there actually are marginal effects present, even
though they were not explicitly included in the model.
The analysis in this section is meant as a small complement to the vast literature on
quantitative trait loci (QTL) and the role of epistasis in settings other than the dose-
response framework. Several comprehensive investigations have been made using model
organisms such as Drosophila melanogaster [15,26] for which there is considerable evi-
dence of the role of epistasis in quantitative traits. How the results of these simple,
2 loci models might translate to larger epistatic networks in other contexts involving
many more loci is yet unclear. However, the simulated models in this study suggest that
epistatic interactions in a dose-response framework may manifest as marginal effects for
each loci involved in the interaction, at least for some configurations of the minor allele
frequency.
Analysis of the anticancer agent etoposide
In this section we apply the the Bayesian neural network to real dose-response data
originally presented in [3]. We focus on the anticancer agent Etoposide which is a topoi-
somerase inhibitor used in the treatment of wide variety of cancers. Etoposide was chosen
for analysis due to the high heritability of cytotoxicity for this compound (approximately
40% heritable) [27] obvserved in previous studies, yet estimatedmarginal effects have only
been able to account for a small fraction of this heritability.
The cytotoxicity of Eptoposide at six concentrations was assessed via cell viability
counts in lymphoblastoid cell lines (LCLs) of 520 individuals of European descent. Geno-
type status for each individual was determined for either 314,621 or 620,901 SNPs, using
HumanHap300 bead chip or HumanQuad610 bead chip platforms [3]. Status for 2.5 mil-
lion total SNPs was imputed using the approach in [28]. Quality control on the 2.5 million
SNPs was performed as in [3]. SNPs failing a test for Hardy-Weinberg equilibrium at the
p = 0.01 level were removed, which resulted in approximately 30,000 SNPs being dis-
carded. QC and initial data preparation were performed using the software package plink
[29]. In the previous section it was shown that even SNPs contributing to genetic risk
through an interaction term only will still most likely result in observed marginal effect.
Using this rationale we first screened for marginal SNP effects using MAGWAS [17]. Fol-
lowing [3], we included temperature, growth rate, the first 3 principal components, and
the experimental batch as covariates in the model. After screening for SNPs with statis-
tically significant marginal effects at the p < 10−5 level, we were left with 41 SNPs for
Beam et al. BioDataMining  (2015) 8:6 Page 13 of 15
analysis by the Bayesian neural network. Genome-wide screening using MAGWAS took
approximately an hour on an Intel i5, quad-core desktop CPU.
We fit a neural network model with 10 hidden units, a logistic activation function and
six Gaussian output units (one for each concentration). Sampling was done for 25 burn-
in iterations, followed by 2,000 iterations to be used for inference. The sampler settings
were as follows: a of step-size 4 ∗ 10−2, L = 20 leap-frog steps per iteration, and an initial
annealing temperature of T0 = 1000. The ARD prior parameters were set to α0 = 5,β0 =
2. Please see [16] for more detail and discussion on these parameter settings. Sampling
took approximately 10 minutes on a GeForce GTX 650 desktop GPU. The HMC analysis
procedure was performed for 3 independent replications and trace plots for each variable
were inspected to assess if parameter estimates had converged.
The top SNP from [3] (rs2076112) has a Bayesian posterior probability which ranks it as
the 20th most important SNP of the 41 SNPs passing the MAGWAS filter. As was found
in [3], several experimental condition variables were found to be very important by the
BNN as well. The top 7 most important variables were all related to experimental and
cellular growth conditions, underscoring the importance of accounting for these condi-
tions as covariates when performing cell-based gene-mapping. The top SNP according
the BNN was rs12650820 (Bayesian probability 0.20, MAGWAS p-value 7.878 ∗ 10−6), a
SNP located on chromosome 4 within the follistatin-like 5 (FSTL5, location 4q32.3) gene.
Dysfunction of FSTL5 has been implicated as biomarker in medulloblastoma, a highly
malignant primary brain cancer [30]. All of the remaining SNPs havemarginal importance
scores which are suggestive of involvement, but less definitive.
Conclusions
In this study we have examined how gene-gene interactions can affect the ability to detect
trait-associated loci in cell-based, dose-response association studies. We have presented
a novel nonparametric procedure in the form of a Bayesian neural network and com-
pared its performance to theMANOVA framework. Using a simulation study of plausible
genetic models and a population genetics based analysis, we have shown that MANOVA
may be able to detect causal loci even in the presence of genetic interactions. Addition-
ally, we have shown that the BNN is also very capable of detecting causal loci across a
range of possible genetic models. Each approach comes with trade-offs - the MANOVA
approach is conceptually more simple and computationally less expensive while the BNN
approach is more flexible and built upon fewer assumptions. In light of the results of this
study, we recommend a two-stage approach (as was used in the Etoposide analysis) as a
viable analysis strategy. MAGWAS is able to screen millions of SNPs quickly for marginal
effects, which will mostly likely be present even if the underlying genetic architecture is
epistatic. Next, the Bayesian neural network can be employed on a smaller subset of SNPs
to explore a richer model space.
It’s also worth discussing some of the modelling benefits offered by the Bayesian neural
network approach. Due to flexibility afforded by the BNN framework, new constraints
or data types can be easily accommodated. Note that to model a new type of data, one
only must be able to write down the likelihood and incorporate this into the output layer
of the network. Thus, when analysing a new type of data, the only change that must be
made is the type of output layer used, which reflects the new data’s likelihood function.
Everything else, such as input layer, hidden layers, and ARD-testing framework, remain
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the same. There is no assumed model and no distributional assumptions, making this
proposed framework very widely applicable to a variety of association mapping scenarios.
More work remains to be done, however, before this approach can be used in a more turn-
key manner. The most immediate improvement that can be made is to the HMC-based
sampler. As with any MCMCmethod, sub-optimal parameter values will result in a chain
failing to converge. The HMC-MCMC sampler used here is no exception and requires
several tuning parameters that can dramatically impact the performance of the approach
as a whole. Most often, several pilot runs are performed to find good values for these
parameters. Recently, several groups have improved upon the generic HMC sampling
scheme we used [31-33] which alleviate some of these issues. Incorporating these recent
advances in HMC sampling techniques will help to make the method more robust and
user-friendly.
In this study we have investigated how genetic interactions may affect the MANOVA
analysis procedure, provided a deeper understanding of how these interactions may affect
dose-response data, and presented a novel Bayesian nonparametric analysis technique.
Cell-based dose-response studies hold much promise for pharmacogenomics, and the
work presented here will help future research efforts utilizing this type of data.
Software availability
Software implementing the approaches outlined in this paper is available at https://
github.com/beamandrew/BNN.
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